The potential DPP-4 inhibitors from Xiao-Ke-An improve the glucolipid metabolism via the activation of AKT/GSK-3β pathway.

European Journal of Pharmacology
Shumin JiangXiao-Ping Zhao

Abstract

Dipeptidyl Peptidase-4 (DPP-4) is a specific enzyme hydrolyzing the incretin hormone glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to reduce insulin secretion, meanwhile DPP-4 inhibitors play an important role in diabetic therapy. In present study, 14 potential inhibitors were screened with an inhibition over 50% on DPP-4 activity from Xiao-Ke-An formula (XKA) and 12 of them exhibited a dose-dependently inhibitory effect at concentrations of 5-50 μmol/l. We found 10 DPP-4 inhibitors restrained differentiation of 3T3-L1 pre-adipocytes as well as reducing the triglycerides and total cholesterol content in 3T3-L1 adipocytes. Furthermore, 7 DPP-4 inhibitors promoted the glucose consumption in insulin-resistance BNL CL.2 cells. Thereinto, ginsenoside Rk1 up-regulated the protein kinase B (AKT) and glycogen synthase kinase-3 (GSK-3β) phosphorylation expression, while kukoamine B and coptisine hydrochloride obviously increased the phosphorylation of AKT protein and columbamine, panaxadiol, ginsenoside Ro, timosaponin AI significantly promoted the phosphorylation of GSK-3β protein. It's our first effort to confirm those seven compounds could serve as DPP-4 inhibitors to attenuate DPP-4 activitie...Continue Reading

References

Oct 7, 2004·Biochemical and Biophysical Research Communications·William C StewartJacqueline M Stephens
Nov 1, 2006·International Journal of Clinical Practice·A Barnett
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
May 5, 2007·Diabetes Research and Clinical Practice·Jongsoon Lee, Myung-Sunny Kim
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Jun 10, 2008·Endocrine, Metabolic & Immune Disorders Drug Targets·Jun YinJianping Ye
Sep 11, 2008·Expert Opinion on Therapeutic Targets·Katrina MacAulay, James R Woodgett
Dec 17, 2008·Pharmacological Reviews·Wook Kim, Josephine M Egan
Apr 16, 2009·British Journal of Pharmacology·Geetha Vani RayasamAbhijit Ray
Nov 4, 2009·Cell Metabolism·Karla F LeavensMorris J Birnbaum
Feb 22, 2011·Gastroenterology·Michael ElashoffPeter C Butler
Dec 23, 2011·Nature·Peng Tian
Jan 9, 2013·International Journal of Biological Macromolecules·Shuang JiangZhiwei Sun
Jan 22, 2014·Fitoterapia·Te-Chun YangWen-Liang Chang
Jun 13, 2015·Future Medicinal Chemistry·Yuanyuan GaoYiming Li
Jan 6, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberUNKNOWN American College of Endocrinology (ACE)
May 23, 2016·Bosnian Journal of Basic Medical Sciences·Tatsuo Tomita
Apr 30, 2017·Expert Opinion on Pharmacotherapy·Kashif M Munir, Elizabeth M Lamos
Mar 3, 2018·Diabetes Research and Clinical Practice·N H ChoB Malanda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.